Related Experiment Videos
Phenelzine treatment of melancholia
Abstract:
Monoamine oxidase (MAO) inhibitor antidepressants are widely thought by clinicians and researchers to be ineffective in the treatment of endogenous depression. This study reports an open clinical trial in which seven of eight outpatients (88%) with melancholia responded to phenelzine treatment. This response rate is comparable to the response to tranylcypromine in a previous study at our clinic. These results suggest that MAO inhibitors are effective for outpatients with endogenous depressive syndromes. The use of MAO inhibitors may be an alternative treatment for patients who cannot tolerate or who have not responded to tricyclic antidepressants.
Insights
Monoamine oxidase (MAO) inhibitors are effective antidepressants for endogenous depression. This open trial showed phenelzine successfully treated melancholia in 88% of outpatients, challenging prior beliefs about MAO inhibitor ineffectiveness.
Area of Science:
- Psychiatry
- Pharmacology
- Clinical Medicine
Background:
- Monoamine oxidase (MAO) inhibitors are often considered ineffective for endogenous depression.
- Existing research and clinical opinion question the efficacy of MAO inhibitors in treating this specific depressive syndrome.
Purpose of the Study:
- To evaluate the effectiveness of phenelzine, a type of MAO inhibitor, in treating outpatients with melancholia (a severe form of depression).
- To challenge the prevailing notion that MAO inhibitors are not effective for endogenous depression.
Main Methods:
- An open clinical trial was conducted.
- Eight outpatients diagnosed with melancholia were treated with phenelzine.
Main Results:
- Seven out of eight (88%) outpatients with melancholia responded positively to phenelzine treatment.
- The observed response rate is comparable to that of tranylcypromine in a previous study at the same clinic.
Conclusions:
- MAO inhibitors, specifically phenelzine, appear to be effective for treating outpatients with endogenous depressive syndromes.
- MAO inhibitors represent a viable alternative treatment option for patients unresponsive to or intolerant of tricyclic antidepressants.